These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 30387005)

  • 1. Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor.
    Cattaneo D; Gervasoni C
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):319-327. PubMed ID: 30387005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
    Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
    Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
    Podany AT; Scarsi KK; Pham MM; Fletcher CV
    Clin Pharmacokinet; 2020 Sep; 59(9):1085-1107. PubMed ID: 32462541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
    Parikh UM; Koss CA; Mellors JW
    Curr HIV/AIDS Rep; 2022 Oct; 19(5):384-393. PubMed ID: 36112336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of cabotegravir for HIV treatment and prevention.
    Canetti D; Spagnuolo V
    Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.
    Scarsi KK; Havens JP; Podany AT; Avedissian SN; Fletcher CV
    Drugs; 2020 Nov; 80(16):1649-1676. PubMed ID: 32860583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
    Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
    Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational HIV integrase inhibitors in phase I and phase II clinical trials.
    Han Y; Mesplède T; Wainberg MA
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1207-1213. PubMed ID: 28956664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
    Bowers GD; Culp A; Reese MJ; Tabolt G; Moss L; Piscitelli S; Huynh P; Wagner D; Ford SL; Gould EP; Pan R; Lou Y; Margolis DA; Spreen WR
    Xenobiotica; 2016; 46(2):147-62. PubMed ID: 26134155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors.
    Yoshinaga T; Seki T; Miki S; Miyamoto T; Suyama-Kagitani A; Kawauchi-Miki S; Kobayashi M; Sato A; Stewart E; Underwood M; Fujiwara T
    Antiviral Res; 2018 Apr; 152():1-9. PubMed ID: 29410019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.
    Radzio-Basu J; Council O; Cong ME; Ruone S; Newton A; Wei X; Mitchell J; Ellis S; Petropoulos CJ; Huang W; Spreen W; Heneine W; García-Lerma JG
    Nat Commun; 2019 May; 10(1):2005. PubMed ID: 31043606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
    Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
    Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.